Literature DB >> 7625716

Cellular mechanisms which distinguish between hormone- and antihormone-activated estrogen receptor.

D P McDonnell1, S L Dana, P A Hoener, B A Lieberman, M O Imhof, R B Stein.   

Abstract

The use of reverse genetics has permitted a definition of the structural features within estrogen receptor required for its productive association with the transcription apparatus. These sequences, transactivation function 1 (TAF1) in the amino terminus and TAF2 at the carboxyl terminus, display distinct transcriptional functions. Using specific receptor mutations it has been shown that on some promoters both TAF1 and TAF2 are required for maximal transcriptional activity, whereas on others, additional factors bound to the target promoter can functionally substitute for TAF1 or TAF2. Estrogen functions as an ER agonist by promoting functional synergism between TAF1 and TAF2. Conversely, 4-OH-tamoxifen inhibits TAF2 activity and functions as an antagonist in cell contexts where TAF2 is required. Alternatively, if a 'TAF2 function' is supplied by another factor, 4-OH tamoxifen can manifest ER agonist activity. These data indicate that alterations in the cellular expression of proteins which mimic TAF1 or TAF2 activity can have a profound effect on the pharmacology of ER modulators. Thus the identification of the cellular proteins which interact with ER and its TAF regions will allow a definition of the mechanism used by the cell to distinguish between hormone- and antihormone-activated estrogen receptor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7625716     DOI: 10.1111/j.1749-6632.1995.tb31374.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  7 in total

Review 1.  Steroid receptor specificity with reference to the estrogen receptor.

Authors:  G H Williams
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

2.  Differential recognition of liganded and unliganded thyroid hormone receptor by retinoid X receptor regulates transcriptional repression.

Authors:  J Zhang; I Zamir; M A Lazar
Journal:  Mol Cell Biol       Date:  1997-12       Impact factor: 4.272

3.  Genetic landscape of clear cell endometrial cancer and the era of precision medicine.

Authors:  Gloria S Huang; Alessandro D Santin
Journal:  Cancer       Date:  2017-05-09       Impact factor: 6.860

4.  Molecular determinants of tissue selectivity in estrogen receptor modulators.

Authors:  T A Grese; J P Sluka; H U Bryant; G J Cullinan; A L Glasebrook; C D Jones; K Matsumoto; A D Palkowitz; M Sato; J D Termine; M A Winter; N N Yang; J A Dodge
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

5.  Classification of breast cancer cells on the basis of a functional assay for estrogen receptor.

Authors:  D K Biswas; L Averboukh; S Sheng; K Martin; D S Ewaniuk; T F Jawde; F Wang; A B Pardee
Journal:  Mol Med       Date:  1998-07       Impact factor: 6.354

Review 6.  Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer.

Authors:  R I Nicholson; J M Gee
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

7.  Human dyskerin binds to cytoplasmic H/ACA-box-containing transcripts affecting nuclear hormone receptor dependence.

Authors:  Federico Zacchini; Giulia Venturi; Veronica De Sanctis; Roberto Bertorelli; Claudio Ceccarelli; Donatella Santini; Mario Taffurelli; Marianna Penzo; Davide Treré; Alberto Inga; Erik Dassi; Lorenzo Montanaro
Journal:  Genome Biol       Date:  2022-08-22       Impact factor: 17.906

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.